Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF2604 - Provider product page
- Provider
- R&D Systems
- Product name
- Human FGF-23 Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human FGF-23 in direct ELISAs and Western blots. In direct ELISAs, approximately 25% cross-reactivity with recombinant mouse FGF-23 is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
Q9GZV9
- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts.
FGF23 is endogenously phosphorylated in bone cells.
FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.
Smith ER, Tan SJ, Holt SG, Hewitson TD
Scientific reports 2017 Jun 13;7(1):3345
Scientific reports 2017 Jun 13;7(1):3345
FGF23 is endogenously phosphorylated in bone cells.
Lindberg I, Pang HW, Stains JP, Clark D, Yang AJ, Bonewald L, Li KZ
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2015 Mar;30(3):449-54
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2015 Mar;30(3):449-54
FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.
Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG
The Journal of clinical investigation 2012 Jul;122(7):2543-53
The Journal of clinical investigation 2012 Jul;122(7):2543-53
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Cell Proliferation Induced by FGF-23 and Neutralization by Human FGF-23 Antibody. In the presence of Recombinant Mouse Klotho (5 µg/mL, Catalog # 1819-KL) and heparin (10 µg/mL), Recombinant Human FGF-23 (Catalog # 2604-FG) stimulates proliferation in the NIH-3T3 mouse embryonic fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, proliferation elicited by Recombinant Human FGF-23 (1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human FGF-23 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2604). The ND50 is typically 5-15 µg/mL.